FDA has never safety tested Aluminum in vaccines. Instead,in 1975 FDA grandfathered in Aluminum with no testing declaring it Generally Recognized As Safe (GRAS). Below are some of the studies that FDA never considered.
Precautions in Pediatric Immunization Procedures
In August 1953, the Journal of the American Medical Association (JAMA) published Precautions in Pediatric Immunization Procedures, written by Louis W. Sauer, M.D., Ph.D. The paper describes “problems” in mass-vaccinating children with aluminum-containing vaccines, due to febrile reactions, aluminum cysts at the site of injection, post-vaccination encephalopathy (brain dysfunction, disease, or disorder), paralytic poliomyelitis of the injected limb, and other unfavorable results.
Aluminum Sulfate – Material Safety Data Sheet
Section 11 of the MSDS for aluminum sulfate states: “Symptoms may include cramping, nausea, vomiting, diarrhea. Ingestion also produces a feeling of dryness and puckering of the mucous membranes of the mouth and throat. It may affect behavior/central nervous system and cause ataxia and seizures. High blood concentrations of aluminum may cause aluminum-induced encephalopathy with confusion, lethargy, respiratory depression, cognitive impairment, dysarthria, asterixis, seizure, coma. It may also affect the liver. Individuals with renal failure may more readily accumulate toxic levels of aluminum which can result in encephalopathy and seizures.
Experimental Epilepsy in the Monkey Following Multiple Intracerebral Injections of Alumina Cream
The multiple intracerebral injection of alumina cream (aluminum hydroxide cream) into a principal cerebral sensorimotor cortical area is effective in producing chronic epilepsy in monkeys. Some of the clinical, pathological and electroencephalographic features of such epileptic animals, supplemented by a motion picture demonstration of a reactive monkey are the subject of the present report.